에 대한 최신 뉴스 Guardant Health (NASDAQ:GH) 주식

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Equities

Mid Cap

News

Movers

Trading Ideas

HIMX

OKLO

RGTI

SGHC

이들 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 오클로(NYSE:OKLO)의 주식은 금요일 회사가 R파워와 데이터 센터를 위한 청정 에너지 제공에 대한 MoU를 체결했다고 발표한 후 72.60% 상승했다.

오클로 및 리제티 컴퓨팅 등 지난주 최대 상승한 8개의 중형주 (1월 20일-1월 24일)

CPRI

NARI

PAYX

PLUG

PYCR

SWTX

이들 11개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 이나리 메디컬(NASDAQ:NARI)의 주식은 스트라이커(NYSE:SYK)이 주당 80달러 또는 약 49억 달러의 지분 가치를 제시하며 회사를 인수하기로 합의한 후 53.07% 급등했다.

플러그 파워, 카프리 및 프론트라인은 지난주 최대 상승한 중형주 (1월 6일-10일)

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

ETFs

$BTC

AMZN

ARKF

ARKK

ARKW

HOOD

목요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 특히 로빈후드 마켓(NASDAQ:HOOD)를 매입하고 줌 비디오 커뮤니케이션(NASDAQ:ZM)을 매각하는 등 중요한 거래를 했다.
로빈후드 매매

아크 인베스트는 비트코인 반등 속에서 로빈후드 주식 $605만 매수, 줌 주식은 매도

Guardant Health Inc

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX Inc Ordinary Shares - Class A

Gores Holdings IX Inc

Gores Holdings IX Inc Units (1 Ord Class A & 1/3 War)

Gores Holdings IX Inc Warrants (31/01/2027)

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by GREENHEART GOLD INC.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

Tariffs, <a href="https://www.benzinga.com/topic/federal-reserve">federal spending cuts</a> and CoWoS (Chip-on-Wafer-on-Substrate) slowdowns are shaking up the hardware and networking sector. JPMorgan analyst Samik Chatterjee weighs in on which stocks are best equipped to weather the storm.
<h2 class="wp-block-heading">Tariffs: Who's Feeling The Heat?</h2>
Companies loaded with software-driven hardware are dodging the worst of the tariff blow, while commoditized IT hardware players are absorbing rising costs. Networking leaders like Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) have an edge, given their ability to pass costs down the chain.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44005208/nvidia-ai-juggernaut-rolls-on-but-can-arista-cisco-keep-up">Nvidia Dominance Continues As AI Demand Grows: Can Arista, Cisco Keep Up?</a>
Meanwhile, PC and server makers face tighter margins, with limited room to hike prices without losing customers.
Cisco's CFO has already factored in the tariff impact, while Arista's team says they've been planning for China risks ahead of time. The wildcard? 
Storage and networking equipment appear largely insulated, but competitive server pricing could make cost pass-throughs a challenge.
<h2 class="wp-block-heading">Federal Spending Cuts: Who's At Risk?</h2>
A slowdown in government IT budgets might hit device makers harder than infrastructure players. Cisco, with more than 5% of revenue tied to federal spending, could see near-term pressure, but JPMorgan suggests long-term benefits from federal tech modernization. 
Channel partners like CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) also have notable exposure but are downplaying risks for now.
<h2 class="wp-block-heading">CoWoS Cuts: Nvidia's Supply Chain Feels The Squeeze</h2>
Recent CoWoS order cuts by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are reshuffling supplier valuations. The biggest impact? 
Nvidia-linked players like Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), Amphenol Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) could face multiple compression, even if revenue estimates remain intact.
Cisco and Arista look relatively shielded from tariff pain, Nvidia's supply chain faces valuation headwinds and federal spending concerns might be a short-term roadblock for key players.
With hardware margins under pressure, JPMorgan's take is clear: software-rich and infrastructure-driven companies have the best shot at staying ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44214424/move-over-deepseek-not-so-fast-chinas-manus-ai-goes-viral-but-early-users-say-it-crashes-loops-and-fumbles-the-basics">Move Over DeepSeek? Not So Fast: China&#8217;s Manus AI Goes Viral, But Early Users Say It Crashes, Loops, And Fumbles The Basics</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Analyst Ratings

Tech

ANET

COHR

CSCO

NVDA

Cisco, Nvidia, Arista Tackle Tariff Turmoil: Who's Best Positioned?

WIIM

BNTX

BioNTech SE shares are trading lower. The company reported Q4 financial results.

Raymond James analyst John Freeman downgrades Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) from Strong Buy to Outperform and lowers the price target from $81 to $64.

Downgrades

Price Target

Raymond James Downgrades Occidental Petroleum to Outperform, Lowers Price Target to $64

Emerson Electric shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and cut its price target from $135 to $110.

ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) is nearing a deal to snap <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence firm</a>&nbsp;Moveworks.
The purchase could value Moveworks at close to $3 billion, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-10/servicenow-nears-deal-to-buy-ai-assistant-maker-moveworks?sref=TBDibEcD" rel="noreferrer noopener">reports</a>. Moveworks provides companies like Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with AI assistants to handle employee requests.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43788975/amd-closing-competitive-gpu-gap-with-nvidia-gains-market-share-from-intel-in-client-and-server-markets-analyst" rel="noreferrer noopener">AMD Closing Competitive GPU Gap With Nvidia, Gains Market Share From Intel In Client And Server Markets: Analyst</a>
The company, backed by Kleiner Perkins and&nbsp;Lightspeed Venture Partners, was worth $2.1 billion in a&nbsp;2021 funding round.
ServiceNow makes applications that help firms organize and automate their personnel and information technology operations.
Last week, ServiceNow and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) launched AI agents for <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" rel="noreferrer noopener">telecom service improvements</a>.
ServiceNow reported fourth-quarter revenue of $2.96 billion, up 21%, which aligns with <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43320721/servicenow-q4-earnings-revenue-miss-eps-in-line-still-in-early-days-of-massive-ai-opportunity" rel="noreferrer noopener">the&nbsp;consensus estimate</a>. The company reported fourth-quarter adjusted earnings of $3.67 per share, which aligns with analyst estimates.
ServiceNow expects first-quarter subscription revenue of $2.995 billion-$3 billion. ServiceNow held $5.76 billion in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43318968/servicenow-reports-fourth-quarter-and-full-year-2024-financial-results-board-of-directors-authoriz" rel="noreferrer noopener">cash and equivalents</a> as of December 31, 2024.
Price Action: NOW stock is down 3.26% at $822.87 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44200350/salesforce-ai-expansion-sparks-analyst-optimism-400-price-forecast-set" target="_blank" rel="noreferrer noopener">Salesforce Is Trading Below 200-DMA, But Goldman Sachs Sees Huge Stock Upside After Agentforce 2dx Unveil</a></li>
</ul>
Image Via Shutterstock

Media

AVGO

ServiceNow Eyes $3 Billion AI Deal, Targets Boost From Moveworks Chatbot Tech

Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.
The newly launched drug is Prucalopride, a generic version of Resotran&#xAE;. In the United States, Prucalopride is sold under the brand name, Motegrity&#xAE;. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility.
Nora Pharma's Prucalopride is available in blisters packs of 28 tablets for the Canadian market in strengths of 1 mg and 2 mg.

SBFM

Sunshine Biopharma's Nora Pharma Acquires Rights To Two Gastrointestinal Drugs; Already Launched Prucalopride For Chronic Constipation, Second Drug Launch Planned In The Next 9 Months; No Financial Terms Disclosed

Raymond James analyst John Freeman downgrades APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) from Strong Buy to Outperform and lowers the price target from $45 to $32.

Raymond James Downgrades APA to Outperform, Lowers Price Target to $32

No gainer in today's Pre-market session. 
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">214.53</td>
<td align="right">-4.01</td>
<td align="right">-1.84</td>
<td>69.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">132.08</td>
<td align="right">-2.17</td>
<td align="right">-1.62</td>
<td>3.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">202.37</td>
<td align="right">-3.30</td>
<td align="right">-1.61</td>
<td>4.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.73</td>
<td align="right">-1.56</td>
<td align="right">-1.56</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.40</td>
<td align="right">-0.72</td>
<td align="right">-1.47</td>
<td>544.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.81</td>
<td align="right">-1.01</td>
<td align="right">-1.16</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">148.21</td>
<td align="right">-1.07</td>
<td align="right">-0.72</td>
<td>10.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.92</td>
<td align="right">-0.37</td>
<td align="right">-0.48</td>
<td>9.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.32</td>
<td align="right">-0.15</td>
<td align="right">-0.36</td>
<td>3.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.70</td>
<td align="right">-0.16</td>
<td align="right">-0.20</td>
<td>32.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 10, 2025

Raymond James analyst Ryan Deschner upgrades Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) from Outperform to Strong Buy and raises the price target from $9 to $29.

Upgrades

TRVI

Raymond James Upgrades Trevi Therapeutics to Strong Buy, Raises Price Target to $29

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and lowers the price target from $290 to $270.

EPAM

Barclays Maintains Overweight on EPAM Systems, Lowers Price Target to $270

On Monday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in <a href="http://Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains" target="_blank" rel="noreferrer noopener">vivo base editing</a>.
The initial safety and efficacy data reported are from all nine patients as of February 26, the data <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214548/beam-therapeutics-announces-positive-initial-data-for-beam-302-in-the-phase-12-trial-in-alpha-1-an" rel="noreferrer noopener">cut-off date</a>.
Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42393770/beam-therapeutics-unveils-new-safety-efficacy-data-from-sickle-cell-disease-candidate-stock-gains" rel="noreferrer noopener">Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains</a>
Alpha-1 antitrypsin (AAT) deficiency is&nbsp;a genetic disorder that can cause lung disease and liver disease.&nbsp;It occurs when the body doesn&#8217;t produce enough AAT, a protein that protects the lungs and liver.&nbsp;
Following a single infusion of BEAM-302, rapid, durable and dose-dependent increases in total AAT, a new production of corrected M-AAT and decreases in mutant Z-AAT were observed in circulation.
<ul>
<li>Changes in total AAT were observed as early as Day 7, plateaued around Day 21 and were maintained for the duration of follow-up (up to Month 6 in the 15 mg cohort, Month two in the 30 mg cohort and Day 28 in the 60 mg cohort).</li>
<li>Increased total AAT was functional.</li>
</ul>
Beam plans to continue the dose-escalation portion of Part A of the ongoing Phase 1/2 trial, including enrolling and dosing a fourth dose cohort. It also expects to report further data at a medical conference in the second half of 2025.
In addition, the company plans to dose the first patient in Part B, including AATD patients with mild to moderate liver disease, in the second half of 2025.
Concurrently, Beam Therapeutics priced the underwritten offering of 16.15 million shares at $28.48 per share and pre-funded warrants to purchase 1.4 million at $28.47 per pre-funded warrant, with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214581/beam-therapeutics-announces-pricing-of-underwritten-offering" rel="noreferrer noopener">approximately $500 million gross proceeds</a>.
Price Action: BEAM stock is down 3.44% at $27.50 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44217345/whats-going-on-with-palantir-stock-premarket-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Palantir Stock Premarket On Monday?</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Financing

Offerings

General

BEAM

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Barclays analyst Karen Short maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Equal-Weight and raises the price target from $940 to $980.

COST

Barclays Maintains Equal-Weight on Costco Wholesale, Raises Price Target to $980

ServiceNow's agentic AI and automation strengths plus Moveworks' front-end AI assistant and enterprise search technology to accelerate enterprise AI adoption and innovation
Together with Moveworks, ServiceNow will drive use of its agentic AI platform across key growth areas including CRM
ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, today announced it has signed a definitive agreement to acquire Moveworks. The acquisition will combine ServiceNow's agentic AI and automation strengths with Moveworks' front-end AI assistant and enterprise search technology to unlock new experiences for every employee for every corner of the business. Following closing, together with Moveworks, ServiceNow – with thousands of AI agents already deployed – will continue to drive use of its agentic AI ServiceNow Platform to accelerate enterprise adoption and innovation across key growth areas including CRM.
&nbsp;
Transaction details
Under the terms of the agreement, ServiceNow will acquire Moveworks for $2.85 billion, subject to customary purchase price adjustments, payable in a combination of cash and stock. The transaction is expected to close in the second half of 2025, subject to customary regulatory approvals and closing conditions.

ServiceNow Has Signed A Definitive Agreement To Acquire Moveworks For $2.85B

Raymond James analyst John Davis upgrades Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) from Outperform to Strong Buy and announces $140 price target.

FOUR

Raymond James Upgrades Shift4 Payments to Strong Buy, Announces $140 Price Target

Barclays analyst Karen Short maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Equal-Weight and raises the price target from $80 to $115.

Barclays Maintains Equal-Weight on BJ's Wholesale Club, Raises Price Target to $115

Raymond James analyst Patrick O'Shaughnessy upgrades CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) from Market Perform to Outperform and announces $287 price target.

Raymond James Upgrades CME Group to Outperform, Announces $287 Price Target

Macro strategist Raoul Pal has shared his outlook for crypto investors amid recent market volatility, emphasizing that patience and proper risk management are essential for <a href="https://www.benzinga.com/money/bitcoin-price-prediction">surviving this correction</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=W7ZL-nFoynw">podcast</a> on March 1, Pal described the downturn as part of a normal bull market correction, driven by tightening global financial conditions. He explained that &#8220;Financial conditions tightened last year due to the dollar rallying in anticipation of Trump and rising rates ahead of potential tariffs.&#8221;
His core advice centers on risk management: &#8220;If you&#8217;re using leverage, you are going to get blown out and you&#8217;re going to lose control of your tokens.&#8221;
Pal referenced his M2 money supply model, developed with analyst Julian Batella, which has accurately predicted Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price movements with a 10-week lag. 
Addressing Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) 53% decline, Pal dismissed concerns that the asset is failing. He called claims that Solana is a &#8220;scam coin&#8221; or &#8220;dead coin&#8221; nonsense, arguing that SOL remains a deep and robust protocol.
 He also pointed out that its price looks undervalued relative to global M2 trends.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44143660/howard-lutnick-says-president-definitely-thinks-theres-a-bitcoin-strategic-reserve">Howard Lutnick Says &#8216;President Definitely Thinks There&#8217;s A Bitcoin Strategic Reserve&#8217;</a>
What's Next: Despite short-term turbulence, Pal remains optimistic about the bigger picture.
He expects the market to recover by mid-March, calling the current phase the &#8220;healing stage&#8221; and predicts that April, May, and June will mark the second phase of the Banana Zone, ushering in significant bullish price action across the crypto space. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44174606/jpmorgan-questions-viability-of-us-crypto-reserve-cites-issues-with-smaller-tokens">JPMorgan Questions Viability of US Crypto Reserve, Cites Issues With Smaller Tokens</a></li>
</ul>
Image: Shutterstock

$SOL

Raoul Pal Sees Bitcoin, Solana In 'Healing Stage', Predicts Market Recovery In Q2

Outlook
•First Quarter Guidance: Forecasts 7% to 15% sequential revenue growth, revenues of $28.2 million - $30.2 million, Adjusted EBITDA2 loss of $1.8 million to $0.8 million and positive cash flow
•Full Year: Forecasts significant improvements in revenue, adjusted EBITDA, and cash flow

Guidance

Telos Expects Q1 Revenue Of $28.2 M-$30.2M Vs $32.46M Est

Dividends

Safe And Green Development Declares Stock Dividend

Barclays analyst Matt Miksic maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Overweight and raises the price target from $39 to $41.

Barclays Maintains Overweight on Baxter Intl, Raises Price Target to $41

Small Cap

Opinion

Press Releases

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Guardant Health Announces Debt Exchange Transactions

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

AGEN

ALXO

ONCY

RNXT

TSX:ONC

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Guardant Health

뉴스

에 대한 최신 뉴스 Guardant Health (NASDAQ:GH) 주식

월요일, 1월 27, 2025

일요일, 1월 12, 2025

금요일, 8월 09, 2024

금요일, 7월 19, 2024

목요일, 5월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌